Programmed cell death in gouty nephropathy: molecular mechanisms and therapeutic implications
-
By
-
Shengyi Zhao
-
Bingbing Chen
-
He Qian
-
Rong Wang
-
Sanjin Zeng
-
Heguo Yan
-
Jian Zhang
-
Zhaohu Xie
-
Zhaofu Li
-
May 25, 2026
-
Clinical Scorecard: Cellular Death Mechanisms in Gouty Nephropathy: Insights into Molecular Pathways and Treatment Strategies
At a Glance
| Category | Detail |
|---|
| Condition | Gouty Nephropathy |
| Key Mechanisms | Programmed cell death (PCD) pathways including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy contribute to renal injury. |
| Target Population | Patients with gout and chronic kidney disease (CKD) associated with hyperuricemia. |
| Care Setting | Clinical nephrology and rheumatology. |
Key Highlights
- Multiple forms of programmed cell death are simultaneously activated in gouty nephropathy.
- Hyperuricemia and monosodium urate crystals converge on shared upstream stressors.
- Targeting the programmed cell death network offers therapeutic opportunities beyond conventional urate-lowering strategies.
Guideline-Based Recommendations
Diagnosis
- Identify hyperuricemia and assess for urate crystal deposition in kidneys.
Management
- Consider therapies targeting programmed cell death pathways in addition to urate-lowering treatments.
Monitoring & Follow-up
- Monitor renal function and uric acid levels in patients with gout.
Risks
- Persistent hyperuricemia is an independent risk factor for CKD progression.
Patient & Prescribing Data
Patients with gout and chronic kidney disease.
Therapies should address both urate levels and the underlying programmed cell death mechanisms.
Clinical Best Practices
- Recognize the role of programmed cell death in the pathogenesis of gouty nephropathy.
- Implement a multifaceted treatment approach that includes targeting PCD pathways.
Related Resources & Content
